tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

AVIR Stock Latest News

Atea Pharmaceuticals presents three HCV poster presentations at AASLD
The FlyAtea Pharmaceuticals presents three HCV poster presentations at AASLD
3d ago
AVIR
Atea Pharmaceuticals Advances in HCV Treatment Development
PremiumCompany Announcements
Atea Pharmaceuticals Advances in HCV Treatment Development
11d ago
AVIR
Atea Pharmaceuticals files $500M mixed securities shelf
PremiumThe Fly
Atea Pharmaceuticals files $500M mixed securities shelf
11d ago
AVIR
Atea Pharmaceuticals Phase 3 SUNRISE-3 trial did not meet primary endpoint
PremiumThe Fly
Atea Pharmaceuticals Phase 3 SUNRISE-3 trial did not meet primary endpoint
2M ago
AVIR
Atea Pharma publishes data on metabolic activation pathway of bemnifosbuvir
PremiumThe Fly
Atea Pharma publishes data on metabolic activation pathway of bemnifosbuvir
3M ago
AVIR
Atea Pharmaceuticals upgraded to Equal Weight from Underweight at Morgan Stanley
PremiumThe FlyAtea Pharmaceuticals upgraded to Equal Weight from Underweight at Morgan Stanley
3M ago
AVIR
Atea presents initial Phase 2 data for bemnifosbuvir, ruzasvir combination
Premium
The Fly
Atea presents initial Phase 2 data for bemnifosbuvir, ruzasvir combination
6M ago
AVIR
Atea Pharmaceuticals presents new data on combo of bemnifosbuvir, ruzasvir
Premium
The Fly
Atea Pharmaceuticals presents new data on combo of bemnifosbuvir, ruzasvir
6M ago
AVIR
Atea Pharmaceuticals reports Q1 EPS (75c), consensus (61c)
PremiumThe Fly
Atea Pharmaceuticals reports Q1 EPS (75c), consensus (61c)
6M ago
AVIR
Is AVIR a Buy, Before Earnings?
PremiumPre-Earnings
Is AVIR a Buy, Before Earnings?
6M ago
AVIR
Atea Pharmaceuticals announces presentation on safety profile of bemnifosbuvir
PremiumThe Fly
Atea Pharmaceuticals announces presentation on safety profile of bemnifosbuvir
7M ago
AVIR
Atea Pharmaceuticals completes patient enrollment in Phase 3 SUNRISE-3 trial
PremiumThe Fly
Atea Pharmaceuticals completes patient enrollment in Phase 3 SUNRISE-3 trial
8M ago
AVIR
Atea Pharmaceuticals reports Q4 EPS (47c), consensus (51c)
PremiumThe FlyAtea Pharmaceuticals reports Q4 EPS (47c), consensus (51c)
9M ago
AVIR
Atea treatment of disease caused by dengue virus granted FDA orphan status
Premium
The Fly
Atea treatment of disease caused by dengue virus granted FDA orphan status
11M ago
AVIR
Atea Pharmaceuticals’ combination candidate for hepatitis C shows protential
Premium
The Fly
Atea Pharmaceuticals’ combination candidate for hepatitis C shows protential
1y ago
AVIR
Atea Pharmaceuticals reports Q3 EPS (40c), consensus (48c)
PremiumThe Fly
Atea Pharmaceuticals reports Q3 EPS (40c), consensus (48c)
1y ago
AVIR
Buy/Sell: Wall Street’s top 10 stock calls this week
PremiumThe Fly
Buy/Sell: Wall Street’s top 10 stock calls this week
1y ago
W
LLY
Atea Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
PremiumThe Fly
Atea Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
1y ago
AVIR
Atea Pharmaceuticals reports Q2 EPS (34c), consensus (47c)
PremiumThe Fly
Atea Pharmaceuticals reports Q2 EPS (34c), consensus (47c)
1y ago
AVIR
Atea announces first patient dosed in Phase 2 study of bemnifosbuvir, ruzasvir
PremiumThe FlyAtea announces first patient dosed in Phase 2 study of bemnifosbuvir, ruzasvir
1y ago
AVIR
Atea Pharmaceuticals Surges Over on Potential Takeover Bid
Premium
Market News
Atea Pharmaceuticals Surges Over on Potential Takeover Bid
1y ago
AVIR
JNCE
Atea Pharmaceuticals announces U.S. FDA FTD granted to bemnifosbuvir
Premium
The Fly
Atea Pharmaceuticals announces U.S. FDA FTD granted to bemnifosbuvir
2y ago
AVIR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >